BeStock  
Markets › Sectors › Diagnostics & Research

Diagnostics & Research

22 industry stocks in the Diagnostics & Research sector, with a sum of listed market caps of $612.57B. On average they are up 0.20% today and up 32% over the past year.

Stocks22
Sum of listed market caps$612.57B
Average move today▲ 0.20%
Average 1-year return▲ 32.3%
Median P/E36.3
Avg dividend yield0.69%

Leading today

Biggest gainers in this group

  • CRLCharles River▲ 7.83%
  • ADPTAdaptive Biotechnologies▲ 4.29%
  • MEDPMedpace▲ 2.86%

Lagging today

Biggest decliners in this group

  • NTRANatera▼ 14.59%
  • CSTLCastle Biosciences▼ 4.91%
  • WGSGeneDx Holdings▼ 3.09%

Breadth

How many members are up or down right now

15 advancing · 7 declining · 0 unchanged

All 22 stocks, largest first

#StockPriceDay1 yearMarket capP/E (TTM)Yield52-week range
1DHR Danaher$230.25▲ 1.73%▲ 10.3%$161.99B37.70.66%
2IDXX IDEXX Laboratories Inc$676.04▲ 0.79%▼ 4.6%$53.26B45.6–
3A Agilent Technologies$174.76▲ 1.73%▲ 19.8%$49.27B34.50.58%
4NTRA Natera$310.67▼ 14.59%▲ 55.7%$45.05B––
5WAT Waters$457.60▲ 1.00%▲ 23.1%$44.96B191.5–
6IQV IQVIA Holdings$271.83▲ 2.62%▲ 29.2%$44.80B33.1–
7MTD Mettler-Toledo International$1,722.15▲ 2.57%▲ 19.6%$34.25B37.4–
8ILMN Illumina$213.13▲ 2.47%▲ 74.8%$32.23B36.7–
9DGX Quest Diagnostics$255.63▲ 0.35%▲ 44.3%$28.12B25.51.32%
10GH Guardant Health$150.87▼ 1.67%▲ 56.0%$20.41B––
11MEDP Medpace$653.11▲ 2.86%▲ 10.9%$18.27B36.3–
12RVTY Revvity$155.11▲ 2.84%▲ 71.2%$17.31B69.20.18%
13CRL Charles River$337.52▲ 7.83%▲ 100.8%$16.17B366.9–
14ICLR Icon PLC$204.74▲ 1.53%▲ 28.7%$15.34B35.5–
15QGEN Qiagen NV$50.33▼ 1.04%▲ 16.6%$10.39B27.70.70%
16RDNT RadNet$76.00▼ 2.58%▼ 2.9%$5.98B––
17SHC Sotera Health Company$16.01▲ 0.88%▲ 2.1%$4.57B26.7–
18ADPT Adaptive Biotechnologies$27.98▲ 4.29%▲ 89.2%$4.53B––
19WGS GeneDx Holdings$62.37▼ 3.09%▼ 55.4%$1.86B––
20PSNL Personalis$15.79▲ 1.54%▲ 127.8%$1.71B––
21FRNM Freenome$10.18▼ 2.77%▼ 4.9%$1.09B––
22CSTL Castle Biosciences$32.52▼ 4.91%▼ 1.6%$1.00B––

"1 year" is the price change over the past 365 days. P/E is trailing. For reference only, not investment advice.

Scroll to Top